China's Kelun-Biotech has entered into a second collaboration and exclusive license agreement with Merck & Co (NYSE: MRK).
Kelun-Biotech, a holding subsidiary of Sichuan Kelun Pharmaceutical, is teaming up with the US pharma giant, which is known outside North America as MSD, to develop an antibody drug conjugate (ADC) for the treatment of solid tumors.
Under the terms of the agreement, Kelun-Biotech has granted Merck global and exclusive rights to develop, manufacture and commercialize an investigational ADC. The two companies will also collaborate on its early clinical development.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze